Biosimilars

An Argentine firm is scaling up to challenge global pharma giants, promising a more stable supply of a critical drug and a new model for trust in medicine.

A new FDA petition aims to slash drug development costs for copies of even the most complex medicines. Is this the key to global access or a threat to innovation?

Amphastar beats Q2 estimates with new drug sales, but a deeper look reveals pricing pressure, rising costs, and a high-stakes bet on its pipeline.

Biocon's Yesafili, an interchangeable biosimilar to the $5.9B eye drug Eylea, launches in the US, promising major cost savings and market disruption.

Samsung Epis Holdings reports solid growth driven by its biosimilar portfolio, but the real story is its strategic pivot to next-gen cancer drugs and global expansion.

Samsung Bioepis's latest report reveals a thriving biosimilar market, yet deep-seated policy debates over the 340B program threaten to disrupt growth.

With a proven record in biosimilars, new President Dominic Bégin is set to deepen Organon's impact on women's health and healthcare affordability in Canada.

A small biotech is raising millions with a high-risk funding plan to launch a BOTOX alternative. Can it survive long enough to disrupt a pharma titan?

Shilpa Medicare and Orion Corp. partner on a nivolumab biosimilar, challenging Big Pharma and promising affordable access to a vital cancer immunotherapy.

A new partnership between Finland's Orion Pharma and India's Shilpa Medicare aims to bring a lower-cost cancer therapy to Europe, challenging a blockbuster drug.

The $2B market for chronic hives is exploding, with new drugs from Sanofi, Celldex, and Novartis creating a seismic shift for patients and investors.

South Korea's Wellness Innercell targets Indonesia's booming wellness market. Its Surabaya-first strategy reveals a calculated blueprint for navigating Southeast Asia.

For decades, insomnia treatment meant risky sedatives. Now, a new class of drugs is revolutionizing sleep science, promising safer rest for millions.

A new drug from Cambrian Bio shows promise in activating a key metabolic switch. This could lead to treatments that burn fat while preserving muscle mass.

A 'dream team' of pharma veterans has raised $180M to advance a next-gen oral drug, promising to transform the multi-billion dollar IBD market.

At BIO 2026, Transpire Bio isn't just presenting; it's pitching a new paradigm for medicine, using inhalation to tackle everything from diabetes to cancer.

With 33% growth dwarfing industry norms, NNB Nutrition's integrated model and fermentation tech aren't just winning—they're rewriting the rules for wellness.

As a rare Ebola strain rages in a DRC warzone, the G7 pledges massive aid. But with fragile peace deals and no proven cure, is it enough to stop a global crisis?

Quoin Pharma's new data for a rare skin disease shows life-changing results in children, offering hope for families. What do the numbers really mean?